What is Pandorum?
Pandorum Technologies is at the forefront of tissue engineering and regenerative medicine, specializing in the creation of bio-engineered human tissues. Their product pipeline includes advanced solutions such as bio-engineered corneas, mini livers, and lung regeneration therapies. Leveraging cutting-edge technologies like 3D printing and cellular engineering, Pandorum aims to develop functional human tissues for critical applications in medical research and therapeutic interventions. The company's mission is to advance drug discovery and provide novel treatments for a range of medical conditions, with a steadfast commitment to patient safety and care. Pandorum targets healthcare organizations, researchers, and patients, driving progress in human health through scientific innovation.
How much funding has Pandorum raised?
Pandorum has raised a total of $29M across 2 funding rounds:
Other Financing Round
$11M
Series B
$18M
Other Financing Round (2024): $11M with participation from Indian Angel Network
Series B (2026): $18M led by Galentic Pharma Pvt and Avinya Ventures
Key Investors in Pandorum
Indian Angel Network
Indian Angel Network is a prominent network of angel investors focused on backing early-stage businesses with high growth potential. They provide not only capital but also crucial mentoring and strategic guidance to their portfolio companies.
Galentic Pharma Pvt
Galentic Pharma Pvt. Ltd. is a pharmaceutical company established in 1992, specializing in the manufacturing of sterile ophthalmic and non-sterile dermatological products, aiming to provide affordable and quality healthcare solutions.
Avinya Ventures
Avinya Ventures is an early-stage venture capital fund that invests in and mentors innovative startups across various sectors, emphasizing founder-market fit and providing access to a global community.
What's next for Pandorum?
The recent major strategic investment signifies a pivotal moment for Pandorum, positioning the company for significant scaling and market expansion. This capital infusion is anticipated to fuel further research and development, potentially accelerating the commercialization of their bio-engineered tissues. With a focus on regenerative medicine and tissue engineering, Pandorum is poised to make substantial contributions to healthcare, addressing unmet needs in areas like organ transplantation and disease modeling. The company's trajectory suggests a strong emphasis on strategic partnerships and clinical validation to bring their groundbreaking therapies to patients.
See full Pandorum company page
